Angle Share Discussion Threads

[havinthelasttoast] 08/4/2024 20:05

Placing anyone ?

7p tomorrow ?

[zeus19] 08/4/2024 17:37

Very odd day... not a peep from Bones699 or toast during the last 7 hours. Very strange

[htrocka2] 08/4/2024 14:10

'My guess here is that a big order will be announced soon, since the trade show,..'

Sounds about right..

'The AACR Annual Meeting is described as the focal point of the cancer research community, where cutting edge innovations in cancer science and medicine are presented from internationally renowned researchers and institutions. The annual conference is attended by scientists, clinicians, healthcare professionals, patient advocates and industry representatives, with last year's conference attracting over 21,000 attendees'

[muffster] 08/4/2024 11:37

My guess here is that a big order will be announced soon, since the trade show, particularly as better ways of testing the HER2 status of cancers is needed.

[lawson27] 08/4/2024 11:00

Great choice for a few in this years ISA @12.5, GLA

[bagpuss67] 08/4/2024 08:28

It's only an amuse bouche. No way AN will have served up the main course yet..

[waterloo01] 08/4/2024 07:09

Another brick in the wall

The combination of ANGLE's Parsortix system for harvesting CTCs for analysis, BioView's imaging and analysis technologies, and the new HER2 CTC staining kit under development is intended to provide an easy to use assay based on a simple blood test, providing an up-to-date HER2 status for breast cancer patients on a repeat basis.

[waterloo01] 08/4/2024 07:01

GRAIL. Questioning trying to cover all cancers in one test.

Cancer Stage Compared With Mortality as End Points in Randomized Clinical Trials of Cancer Screening

Evidence for this conclusion is stronger for lung than ovarian cancer due to larger sample size (n = 12 vs n = 4 trials) and because reduced cancer mortality by screening has been demonstrated for lung but not ovarian cancer.7-9 For breast cancer, although cancer stage and mortality end points correlated reasonably well (as noted in prior studies10,11), reductions in cancer-specific mortality were smaller than reductions in stage III-IV cancer. The correlation between the 2 end points was weaker for colorectal cancer, and their relationship for prostate cancer was unclear. Stage III-IV cancer incidence is unlikely to be a suitable alternative end point to cancer-specific mortality in screening trials for breast, colorectal, and prostate cancers.



Conclusions and Relevance In randomized clinical trials of cancer screening, incidence of late-stage cancer may be a suitable alternative end point to cancer-specific mortality for some cancer types, but is not suitable for others. These results have implications for clinical trials of multicancer screening tests.

[havinthelasttoast] 08/4/2024 01:26

Rns with placing more like.

[spa362] 07/4/2024 19:35

Maybe - it's about due. Actually, I sense that April could be quite a busy month for announcements, plus results etc. Recent recruitment activity at Angle suggests we are getting into the important commercialization phase now which investors have been waiting for. After that it's just a question of whether Angle grows itself or is bought.

[robizm] 07/4/2024 17:20

Should we get a RNS tomorrow re the bioview post

[gooosed] 07/4/2024 15:12

"A Molecular Voyage: Multi-Omics Insights into Circulating Tumor Cells."


"Abstract
Circulating tumor cells (CTCs) play a pivotal role in metastasis, the leading cause of cancer-associated death. Recent improvements of CTC isolation tools, coupled with a steady development of multiomics technologies at single-cell resolution, have enabled an extensive exploration of CTC biology, unlocking insights into their molecular profiles. A detailed molecular portrait requires CTC interrogation across various levels encompassing genomic, epigenetic, transcriptomic, proteomic and metabolic features. Here, we review how state-of-the-art multiomics applied to CTCs are shedding light on how cancer spreads. Further, we highlight the potential implications of CTC profiling for clinical applications aimed at enhancing cancer diagnosis and treatment."

[havinthelasttoast] 07/4/2024 14:22

Placing at 10p anyone ?

[gooosed] 07/4/2024 11:15

Clearly illustrates the odds of success/failure in drug development which conversely highlights the potential for Parsortix saving time, costs and lives . . . .

[spa362] 06/4/2024 17:14

from the November 2023 trading update:

"the cash position at 2023 year end.... in line with consensus at c. £15 million."

and

"streamlining is expected to deliver cost savings of c. £3 million per annum in 2024 resulting in the extension of the cash runway into Q2 2025."

Overall, year end was expected to be in line with expectations.

Hope this helps

[bones699] 06/4/2024 08:02

Must be down to just loose change from the back of the settee by now lol!

£130m burnt already another £22m chucked on the bon fire 🔥!

[htrocka2] 05/4/2024 22:55

'How many units have they sold this past year.....'....





I'll let you know when the Interims are posted by the end of the month.

[adw198] 05/4/2024 17:11

Probably more cash than in your feral,mistreated kids savings account given you were sacked from AGL and have no alternative employment. Or life.

[zeus19] 05/4/2024 17:10

As confirmed by Andrew Newland, the CEO repeatedly, enough to get to H2 2025. Seems like you're the only one not getting the message you clown

[bones699] 05/4/2024 16:44

How much cash is left chaps?